Piper Jaffray Companies reissued their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report report published on Monday, December 16th, Stock Target Advisor reports. The firm currently has a $104.00 target price on the stock.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. BidaskClub lowered shares of Crispr Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, December 13th. Canaccord Genuity increased their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research note on Wednesday, November 20th. Goldman Sachs Group boosted their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a neutral rating in a research report on Tuesday, November 19th. Finally, Chardan Capital reiterated a buy rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $71.38.
Shares of CRSP opened at $67.23 on Monday. The company has a 50-day simple moving average of $63.51 and a 200-day simple moving average of $50.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The firm has a market capitalization of $3.75 billion, a P/E ratio of -19.54 and a beta of 3.31. Crispr Therapeutics has a 52 week low of $24.56 and a 52 week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, equities analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 over the last quarter. 21.40% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of CRSP. Millennium Management LLC bought a new stake in Crispr Therapeutics in the 3rd quarter valued at $4,366,000. Orbimed Advisors LLC bought a new position in Crispr Therapeutics during the 3rd quarter worth about $21,167,000. Granahan Investment Management Inc. MA raised its stake in shares of Crispr Therapeutics by 8.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after purchasing an additional 2,655 shares during the period. Barclays PLC lifted its holdings in shares of Crispr Therapeutics by 42.7% in the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Stifel Financial Corp lifted its holdings in shares of Crispr Therapeutics by 18.0% in the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after purchasing an additional 1,491 shares in the last quarter. Institutional investors and hedge funds own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.